Redox potential status in children with perinatal HIV-1 infection treated with zidovudine.
de Martino
M
M
Zammarchi
E
E
Filippi
L
L
Donati
M A
MA
Mannelli
F
F
Galli
L
L
Vierucci
A
A
D020155:3-Hydroxybutyric Acid; D000090:Acetoacetates / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D008928:Mitochondria / Q000187:drug effects*; D010084:Oxidation-Reduction / Q000187:drug effects; D011773:Pyruvates / Q000097:blood; D019289:Pyruvic Acid; D015215:Zidovudine / Q000627:therapeutic use*
D000090:Acetoacetates; D006885:Hydroxybutyrates; D007773:Lactates; D011773:Pyruvates; D019344:Lactic Acid; D015215:Zidovudine; C016635:acetoacetic acid; D019289:Pyruvic Acid; D020155:3-Hydroxybutyric Acid